Steven L. Basta - Apr 3, 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
President and CEO, Director
Signature
/s/ Molly Henderson, Attorney-in-Fact for Steven L. Basta
Stock symbol
PHAT
Transactions as of
Apr 3, 2025
Transactions value $
$0
Form type
4
Date filed
4/3/2025, 05:30 PM
Previous filing
Apr 3, 2025
Next filing
Sep 26, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Performance Shares Award $0 +360K $0.00 360K Apr 3, 2025 Common Stock 360K Direct F1, F2
transaction PHAT Stock Option (Right to Buy) Award $0 +1.09M $0.00 1.09M Apr 3, 2025 Common Stock 1.09M $5.01 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit represents a contingent right to receive one share of common stock of the Issuer.
F2 The performance stock units will vest based on the achievement of stock price hurdles and service-based vesting requirements over a period of four years following the grant date.
F3 The stock option will vest with respect to 25% of the shares of common stock on April 3, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.